Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Decreases By 33.4%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 11,060,000 shares, a drop of 33.4% from the January 31st total of 16,610,000 shares. Based on an average daily volume of 4,110,000 shares, the short-interest ratio is currently 2.7 days.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Friday, February 7th. Stifel Nicolaus lowered their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, November 14th.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 76,473 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last ninety days. Insiders own 1.62% of the company's stock.

Remove Ads

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently modified their holdings of the business. State Street Corp grew its position in shares of X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company's stock worth $1,976,000 after buying an additional 189,105 shares during the period. Verition Fund Management LLC bought a new position in X4 Pharmaceuticals during the 3rd quarter worth approximately $30,000. XTX Topco Ltd boosted its stake in X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after acquiring an additional 46,397 shares during the last quarter. SG Americas Securities LLC boosted its stake in X4 Pharmaceuticals by 233.0% during the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock worth $134,000 after acquiring an additional 128,148 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock worth $166,000 after acquiring an additional 126,296 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company's stock.

X4 Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:XFOR traded up $0.00 during trading on Wednesday, hitting $0.37. 1,601,576 shares of the company's stock were exchanged, compared to its average volume of 2,975,245. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.57. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm has a market cap of $62.76 million, a P/E ratio of -4.09 and a beta of 0.39.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.